AVLN (AVLN) Stock Price & Analysis
AVLN (AVLN) rose 2.17% to USD 28.67 as of June 10, 2026 at 11:05 UTC, according to Nexqual real-time market data.
AVLN last closed at USD 28.06; the session ranged USD 27.26–29.41 on volume of 199,412 shares. Market capitalization is $1.27B, with a 52-week range of USD 24.15–32.23 (NMS). Source: Nexqual, June 10, 2026 at 11:05 UTC.
Key Statistics (as of June 10, 2026 at 11:05 UTC)
| Price | USD 28.67 |
|---|---|
| Change | ▲ 2.17% (up) |
| Previous Close | USD 28.06 |
| Open | USD 28.19 |
| Day Range | USD 27.26 – 29.41 |
| 52-Week Range | USD 24.15 – 32.23 |
| Volume | 199,412 shares |
| Market Cap | $1.27B |
| Exchange | NMS |
Technical Analysis (AVLN)
Nexqual's technical model rates AVLN "NEUTRAL" based on 1 bullish and 2 bearish signals across 27 daily candles, as of June 10, 2026 at 11:05 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 49.53 (neutral) |
| MACD | -0.72 (negative) |
Analyst Ratings (AVLN)
Wall Street analysts rate AVLN "Strong Buy" based on 4 analysts, with a mean price target of USD 59 (range USD 51–80), per Nexqual as of June 10, 2026 at 11:05 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 59 |
| High Target | USD 80 |
| Low Target | USD 51 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (AVLN)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.57 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -21.83 vs est -0.82 ▼ miss |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Financials & Fundamentals (AVLN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -68.34% |
| Current Ratio | 10.19 |
| Free Cash Flow | $-50.58M |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Financial Health Score (AVLN)
Nexqual rates AVLN's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 11:05 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — No data |
| Cash Flow | Weak — Operating cash flow -$81M |
| Efficiency | Critical — ROE -68%, ROA -41.7% |
Ownership (AVLN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +49.91% |
| Shares Outstanding | 44.33M |
| Float | 14.45M |
| Short % of Float | +2.02% |
Source: Nexqual, June 10, 2026 at 11:05 UTC.
Leadership (AVLN)
AVLN is led by Lyn Baranowski (age 49), CEO, President & Director, per Nexqual as of June 10, 2026 at 11:05 UTC.
| CEO, President & Director | Lyn Baranowski (age 49) |
|---|---|
| CFO & Chief Business Officer | Douglas R. Carlson (age 46) |
| Chief Operating Officer | Melissa Rhodes DABT (age 47) |
| Senior Director of IR & Corporate Communications | Cassie Saitow |
| Senior Vice President of Clinical Development | Craig Conoscenti |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COAG | Hemab Therapeutics Holdings, In | USD 27 | ▲ 6.72% |
| SPTX | Seaport Therapeutics, Inc. | USD 17.66 | ▲ 7.42% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| ODTX | Odyssey Therapeutics, Inc. | USD 17.09 | ▲ 4.02% |
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 11:05 UTC. This page is informational and not investment advice.